Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29‐month follow‐up from a randomized, open‐label, phase III trial

Documents similaires

• Administration of nivolumab plus ipilimumab: Infusion of the fixed‐ratio combination versus sequential infusions in two randomized controlled trials of metastatic melanoma (CheckMate 742) and renal cell carcinoma (CheckMate 800)
  par: Alexander M. Menzies, et autres
  Publié: (2025)
• Prognostic factors for patients with esophageal cancer who achieve pathological complete response in the primary tumor after upfront chemotherapy or chemoradiotherapy
  par: Masaaki Motoori, et autres
  Publié: (2025)
• Scaling CheckMate for Game-Theoretic Security
  par: Rain, Sophie, et autres
  Publié: (2024)
• Correction to “Nivolumab Plus Chemotherapy or Ipilimumab Versus Chemotherapy in Patients With Advanced Esophageal Squamous Cell Carcinoma ( CheckMate 648): 29‐Month Follow‐Up From a Randomized, Open‐Label, Phase III Trial”
  Publié: (2025)
• CheckMate: Evaluating Checkpointing Protocols for Streaming Dataflows
  par: Siachamis, George, et autres
  Publié: (2024)